Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: Prediction of future prostate volume in individual men

Prostate

Volumn 67, Issue 16, 2007, Pages 1816-1824

  Bosch, J L H R ^a   Tilling, K ^b   Bohnen, A M ^c   Bangma, C H ^c   Donovan, J L ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Benign prostatic hyperplasia; Prostate growth; Total prostate volume; Transition zone volume; Watchful waiting

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BIVARIATE ANALYSIS; CALCULATION; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; GROWTH CURVE; HUMAN; HUMAN TISSUE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; ORGAN GROWTH; ORGAN SIZE; PREDICTION; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY;

AGE FACTORS; AGED; COHORT STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, STATISTICAL; ORGAN SIZE; PROSTATE; REFERENCE VALUES;

EID: 36849025533     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20663     Document Type: Article

References (24)

1. Hald T. Urodynamics in benign prostatic hyperplasia: A survey. Prostate 1989; Suppl 2:69-77.
2. Bosch J, Hop W, Niemer A, Bangma C, Kirkels W, Schroeder F. Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. J Urol 1994;152:1501-1505.
3. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J. Serum prostate-specific antigen is a powerful predictor of acute urinary retention and the need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999;53:473-480.
4. Marberger MJ, Andersen JT, Nickel JC, Malice JC, Gabriel M, Pappas F, Meehan A, Stoner E, Waldstreicher J. Prostate volume and serum prostate-specific antigen as predictors of acute retention. Eur Urol 2000;38:563-568.
5. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 1999;161:1174-1179.
6. Corica FA, Jacobsen SJ, King BF, Bostwick DG, Jacobson DJ, Girman CJ, Lieber MM. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men. J Urol 1999;161:831-834.
7. Rhodes T, Girman CJ, Jacobsen DJ, Roberts RO, Lieber MM, Jacobsen SJ. Longitudinal prostate volume in a community-based sample: 7 year followup in the Olmsted County study of urinary symptoms and health status among men (abstract). J Urol 2000;163(suppl 4):249.
8. Roehrborn CG, McConnell JD, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, Schellhammer PF, Bruskewitz R, Matsumoto AM, Harrison LH, Fuselier HA, Walsh P, Roy J, Andriole G, Resnick M, Waldstreicher J. Serum prostate-specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 2000;163:13-120.
9. Masumori N, Tsukamoto T, Kumamoto Y, Miyake H, Rhodes T, Girman CJ, Guess HA, Jacobsen SJ, Lieber MM. Age-related differences in internal prostatic architecture on transrectal ultrasonography: Results of a community based survey in Japan. J Urol 1997;157:1718-1722.
10. Bosch JL, Bohnen AM, Groeneveld FP, Bernsen R. Validity of three calliper-based transrectal ultrasound methods and digital rectal examination in the estimation of prostate volume and its changes with age: The Krimpen study. Prostate 2005;62:353-363.
11. St Sauver JL, Jacobson DJ, Girman CJ, Lieber MM, McGree ME, Jacobsen SJ. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. J Urol 2006;175(3 Pt 1):1018-1022.
12. Blanker MH, Groeneveld FPMJ, Prins A, Bernsen RMD, Bohnen AM, Bosch JLHR. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: The Krimpen study of male urogenital tract problems and general health status. BJU Int 2000;85:665-671.
13. Blanker MH, Prins J, Bosch JLHR, Schouten BWV, Bernsen RMD, Groeneveld FPMJ, Bohnen AM. Loss to follow-up in a longitudinal study on urogenital symptoms in Dutch older men. Urol Int 2005;75:30-37.
14. Kaplan SA, Te AE, Pressler LB, Olsson CA. Transition zone index as a method of assessing benign prostatic hyperplasia: Correlation with symptoms, urine flow and detrusor pressure. J Urol 1995;154:1764-1769.
15. McNeal J. Pathology of benign prostatic hyperplasia. Insight into its etiology. Urol Clin N Am 1990;17:477-486.
16. Torp-Pedersen S, Juul N, Jakobsen H. Transrectal prostatic ultrasonography. Equipment, normal findings, benign hyperplasia and cancer. Scand J Urol Nephrol Suppl 1988;107:19-25.
17. Lindsey J. Models for repeated measurements. Oxford: Oxford Science Publications. 1993.
18. Goldstein H. Multilevel Statistical Models. 2nd edition. London: Edward Arnold. 1995.
19. Tilling K, Sterne JA, Wolfe CD. Multilevel growth curve models with covariate effects: Application to recovery after stroke. Stat Med 2001;20:685-704.
20. Bosch JLHR, Hop WCJ, Kirkels WJ, Schröder FH. Prostate specific antigen in a community-based sample of men without prostate cancer: Correlations with prostate volume, age, body mass index and symptoms of prostatism. Prostate 1995;27:241-249.
21. Woodhouse G. Multilevel modelling applications: A guide for Users of MLn, 1996.
22. StataCorp. Stata Statistical Software: Release 5.0. College Station. Texas: Stata corporation. 1997.
23. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398.
24. Kok ET, Bohnen AM, Jonkheim R, Gouweloos J, Groeneveld FPMJ, Thomas S, Bosch JLHR. A simple case definition of clinical benign prostatic hyperplasia, based on the international prostate symptom score predicts general practitioner consultation rates. Urology 2006;68:784-789.